Agilent Technologies, Inc. (A) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $129.31 (-0.98%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Apr 14, 2026 | Luke Sergott | Barclays | $140.00 | +8.3% |
| Nov 25, 2025 | Daniel Arias | Stifel Nicolaus | $170.00 | +31.5% |
| Nov 25, 2025 | Catherine Ramsey Schulte | Robert W. Baird | $165.00 | +27.6% |
| Aug 28, 2025 | Brandon Couillard | Wells Fargo | $140.00 | +8.3% |
| Oct 15, 2024 | Luke Sergott | Barclays | $145.00 | +12.1% |
| Oct 14, 2024 | Patrick Donnelly | Citigroup | $165.00 | +27.6% |
| Oct 1, 2024 | Vijay Kumar | Evercore ISI | $145.00 | +12.1% |
| Aug 22, 2024 | Michael Ryskin | Bank of America Securities | $147.00 | +13.7% |
| Jul 22, 2024 | Brandon Couillard | Jefferies | $135.00 | +4.4% |
| May 30, 2024 | Daniel Arias | Stifel Nicolaus | $151.00 | +16.8% |
| May 30, 2024 | Catherine Schulte | Robert W. Baird | $136.00 | +5.2% |
| May 30, 2024 | Matthew Sykes | Goldman Sachs | $145.00 | +12.1% |
| Apr 4, 2024 | Daniel Arias | Stifel Nicolaus | $163.00 | +26.1% |
| Nov 20, 2023 | Jack Meehan | Barclays | $105.00 | -18.8% |
| Nov 20, 2023 | Ross Muken | Evercore ISI | $120.00 | -7.2% |
| Jan 10, 2023 | Dan Leonard | Wells Fargo | $170.00 | +31.5% |
| Nov 22, 2022 | Puneet Souda | Leerink Partners | $165.00 | +27.6% |
| May 25, 2022 | Catherine Schulte | Robert W. Baird | $161.00 | +24.5% |
| Apr 29, 2022 | Timothy Daley | Wells Fargo | $130.00 | +0.5% |
Top Analysts Covering A
A vs Sector & Market
| Metric | A | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.06 | 2.24 | 2.41 |
| Analyst Count | 18 | 8 | 19 |
| Target Upside | +19.6% | +11475.0% | +17.1% |
| P/E Ratio | 26.17 | 4.00 | 31.98 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-10-31 | $7.35B | $7.40B | $7.46B | 12 |
| 2027-01-31 | $1.90B | $1.91B | $1.92B | 4 |
| 2027-04-30 | $1.90B | $1.92B | $1.92B | 6 |
| 2027-07-31 | $1.94B | $1.95B | $1.96B | 4 |
| 2027-10-31 | $2.08B | $2.10B | $2.11B | 7 |
| 2028-01-31 | $2.00B | $2.01B | $2.02B | 3 |
| 2028-04-30 | $2.00B | $2.01B | $2.02B | 5 |
| 2028-07-31 | $2.04B | $2.05B | $2.06B | 3 |
| 2028-10-31 | $2.16B | $2.17B | $2.18B | 6 |
| 2029-10-31 | $8.73B | $8.82B | $8.89B | 5 |
| 2030-10-31 | $9.21B | $9.30B | $9.38B | 5 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-10-31 | $5.92 | $5.97 | $6.00 | 11 |
| 2027-01-31 | $1.50 | $1.51 | $1.52 | 6 |
| 2027-04-30 | $1.55 | $1.56 | $1.57 | 3 |
| 2027-07-31 | $1.65 | $1.67 | $1.68 | 3 |
| 2027-10-31 | $1.85 | $1.86 | $1.88 | 6 |
| 2028-01-31 | $1.59 | $1.61 | $1.62 | 8 |
| 2028-04-30 | $1.66 | $1.68 | $1.69 | 4 |
| 2028-07-31 | $1.77 | $1.78 | $1.80 | 5 |
| 2028-10-31 | $2.00 | $2.02 | $2.03 | 8 |
| 2029-10-31 | $7.94 | $8.04 | $8.13 | 1 |
| 2030-10-31 | $8.49 | $8.61 | $8.70 | 1 |
Frequently Asked Questions
What is the analyst consensus for A?
The consensus among 18 analysts covering Agilent Technologies, Inc. (A) is Buy with an average price target of $168.18.
What is the highest price target for A?
The highest price target for A is $170.00, set by Daniel Arias at Stifel Nicolaus on 2025-11-25.
What is the lowest price target for A?
The lowest price target for A is $105.00, set by Jack Meehan at Barclays on 2023-11-20.
How many analysts cover A?
18 analysts have issued ratings for Agilent Technologies, Inc. in the past 12 months.
Is A a buy or sell right now?
Based on 18 analyst ratings, A has a consensus rating of Buy (2.06/5) with a +19.6% upside to the consensus target of $168.18.
What are the earnings estimates for A?
Analysts estimate A will report EPS of $5.97 for the period ending 2026-10-31, with revenue estimated at $7.40B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.